An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients

Inclusion Criteria Patients must have: AIDS or other immunocompromising condition. Candidal esophagitis. Life expectancy of at least 2 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Evidence of non-candidal systemic fungal infection. Abnormalities that may preclude esophagoscopy or endoscopy. Unable to tolerate fluconazole. Unable to give informed consent. Enrollment in other experimental trials of approved or non-approved drugs or systemic compounds (unless approved by the Pfizer Clinical Monitor). Other condition that would make patient unsuitable for enrollment. Concurrent Medication: Excluded: Concomitant oral or topical antifungal agent. Other experimental medications. Patients with the following prior condition are excluded: History of allergy to imidazoles or azoles. Prior Medication: Excluded: Any oral or topical antifungal therapy within the past 3 days. Active use of illicit or illegal drugs.